Genetic subtype-guided immunochemotherapy in relapsed and refractory diffuse large B cell lymphoma: a phase 2 investigator-initiated nonrandomized clinical trial (GUIDANCE-06)

Study design and participants

This phase 2 single-arm, open-label trial (ClinicalTrials.gov NCT05348213) adopted a prospective cohort design. Enrollment was restricted to R/R DLBCL patients. Participant inclusion criteria included: age 18–75…